JP2020524139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524139A5 JP2020524139A5 JP2019569312A JP2019569312A JP2020524139A5 JP 2020524139 A5 JP2020524139 A5 JP 2020524139A5 JP 2019569312 A JP2019569312 A JP 2019569312A JP 2019569312 A JP2019569312 A JP 2019569312A JP 2020524139 A5 JP2020524139 A5 JP 2020524139A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- subject
- composition according
- myelofibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024027645A JP2024075579A (ja) | 2017-06-14 | 2024-02-27 | 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762519725P | 2017-06-14 | 2017-06-14 | |
| US62/519,725 | 2017-06-14 | ||
| US201862679210P | 2018-06-01 | 2018-06-01 | |
| US62/679,210 | 2018-06-01 | ||
| PCT/US2018/037213 WO2018231905A1 (en) | 2017-06-14 | 2018-06-13 | Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024027645A Division JP2024075579A (ja) | 2017-06-14 | 2024-02-27 | 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524139A JP2020524139A (ja) | 2020-08-13 |
| JP2020524139A5 true JP2020524139A5 (https=) | 2021-07-29 |
| JP7496686B2 JP7496686B2 (ja) | 2024-06-07 |
Family
ID=64660712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569312A Active JP7496686B2 (ja) | 2017-06-14 | 2018-06-13 | 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 |
| JP2024027645A Pending JP2024075579A (ja) | 2017-06-14 | 2024-02-27 | 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024027645A Pending JP2024075579A (ja) | 2017-06-14 | 2024-02-27 | 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200101134A1 (https=) |
| EP (2) | EP4454707A3 (https=) |
| JP (2) | JP7496686B2 (https=) |
| CN (1) | CN111050770A (https=) |
| DK (1) | DK3638243T3 (https=) |
| ES (1) | ES2991738T3 (https=) |
| FI (1) | FI3638243T3 (https=) |
| HR (1) | HRP20241477T1 (https=) |
| HU (1) | HUE068733T2 (https=) |
| LT (1) | LT3638243T (https=) |
| PL (1) | PL3638243T3 (https=) |
| PT (1) | PT3638243T (https=) |
| RS (1) | RS66093B1 (https=) |
| SI (1) | SI3638243T1 (https=) |
| SM (1) | SMT202400437T1 (https=) |
| WO (1) | WO2018231905A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| CN108350057A (zh) | 2015-05-20 | 2018-07-31 | 细胞基因公司 | 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法 |
| MA45811A (fr) | 2016-07-27 | 2019-06-05 | Acceleron Pharma Inc | Méthodes et compositions de traitement de maladie. |
| NZ754161A (en) | 2016-11-10 | 2025-11-28 | Keros Therapeutics Inc | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| JP7663502B2 (ja) * | 2018-10-31 | 2025-04-16 | セルジーン コーポレイション | 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2021189019A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| US20230181690A1 (en) * | 2020-04-13 | 2023-06-15 | Celgene Corporation | Methods for treating anemia using an actriib ligand trap and fedratinib |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CA3177632A1 (en) * | 2020-05-15 | 2021-11-18 | Melih ACAR | Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| WO2022271716A2 (en) * | 2021-06-21 | 2022-12-29 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii signaling inhibitors |
| KR20240051971A (ko) * | 2021-08-19 | 2024-04-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 ii형 신호전달 억제제를 이용한 방법 |
| WO2025137373A1 (en) * | 2023-12-19 | 2025-06-26 | Cellarity, Inc. | Disease detection systems and methods |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| NZ306767A (en) | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| TW201803586A (zh) | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| AU2010282361B2 (en) | 2009-08-13 | 2015-03-19 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
| KR20140084211A (ko) | 2011-10-17 | 2014-07-04 | 악셀레론 파마 인코포레이티드 | 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물 |
| JP2017509647A (ja) | 2014-03-21 | 2017-04-06 | アクセルロン ファーマ， インコーポレイテッド | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
| CN114699529A (zh) * | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| US20180125928A1 (en) * | 2015-05-13 | 2018-05-10 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
| CN108348578B (zh) * | 2015-08-04 | 2022-08-09 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| EP3380121B1 (en) * | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
| MA45811A (fr) | 2016-07-27 | 2019-06-05 | Acceleron Pharma Inc | Méthodes et compositions de traitement de maladie. |
-
2018
- 2018-06-13 PL PL18816685.4T patent/PL3638243T3/pl unknown
- 2018-06-13 DK DK18816685.4T patent/DK3638243T3/da active
- 2018-06-13 SI SI201831166T patent/SI3638243T1/sl unknown
- 2018-06-13 PT PT188166854T patent/PT3638243T/pt unknown
- 2018-06-13 WO PCT/US2018/037213 patent/WO2018231905A1/en not_active Ceased
- 2018-06-13 RS RS20241154A patent/RS66093B1/sr unknown
- 2018-06-13 FI FIEP18816685.4T patent/FI3638243T3/fi active
- 2018-06-13 EP EP24186606.0A patent/EP4454707A3/en active Pending
- 2018-06-13 JP JP2019569312A patent/JP7496686B2/ja active Active
- 2018-06-13 LT LTEPPCT/US2018/037213T patent/LT3638243T/lt unknown
- 2018-06-13 HR HRP20241477TT patent/HRP20241477T1/hr unknown
- 2018-06-13 HU HUE18816685A patent/HUE068733T2/hu unknown
- 2018-06-13 ES ES18816685T patent/ES2991738T3/es active Active
- 2018-06-13 EP EP18816685.4A patent/EP3638243B1/en active Active
- 2018-06-13 SM SM20240437T patent/SMT202400437T1/it unknown
- 2018-06-13 CN CN201880052595.1A patent/CN111050770A/zh active Pending
- 2018-06-13 US US16/621,866 patent/US20200101134A1/en not_active Abandoned
-
2024
- 2024-02-27 JP JP2024027645A patent/JP2024075579A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524139A5 (https=) | ||
| JP6887212B2 (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| Gimenez et al. | TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation | |
| JP2020183389A5 (https=) | ||
| EP2515926A1 (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| CN116261463A (zh) | 治疗痛风的方法 | |
| US20250188158A1 (en) | Treatment of Parkinson's Disease | |
| TW202432135A (zh) | 藉由投予（ｒ）－２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－氧雜環丁－３－基）哌𠯤－１－基］戊－２－烯腈治療免疫性血小板減少症的方法 | |
| CN107106645A (zh) | 用于治疗c‑met相关性癌症的方法和组合物 | |
| CN116867505A (zh) | 替西帕肽治疗方法 | |
| US20230151107A1 (en) | Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19 | |
| WO2023122355A2 (en) | Methods of treating or preventing infusion-related reactions | |
| CN113631181A (zh) | 度拉糖肽的治疗用途 | |
| AU2018228246A1 (en) | Preventive or therapeutic agent for HTLV-1-associated myelopathy using low-dose anti-CCR4 antibody | |
| WO2020201444A1 (en) | Repurposing small molecules for senescence-related diseases and disorders | |
| EP3381934B1 (en) | Protein for neutralizing programmed necrocytosis promotion antibody, and application of protein | |
| Mekahli et al. | FC 130 RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3B TRIAL OF TOLVAPTAN IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): 1-YEAR DATA | |
| KR102561720B1 (ko) | 종양에 대한 직접적인 억제 효과를 갖는 인터페론의 결정 방법 및 그 용도 | |
| CN108992671A (zh) | 一种药物组合物及其制备治疗肝损伤的药物中的用途 | |
| RU2848183C1 (ru) | Лечение болезни паркинсона | |
| CN108992660A (zh) | 人sDR5-Fc重组融合蛋白作为胰腺炎治疗药物的应用 | |
| WO2025223394A1 (en) | Combination therapy for classic hodgkin's lymphoma | |
| Neroeva et al. | Features of local expression of genes of immune response cytokines and trophic and vasoregulatory factors in modeling of retinal pigment epithelium atrophy | |
| US20240148827A1 (en) | Methods and Compositions for Treatment of Disease | |
| TW202440120A (zh) | 藉由投予（ｒ）－２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑并［３，４－ｄ］嘧啶－１－基］六氫吡啶－１－羰基］－４－甲基－４－［４－（氧雜環丁－３－基）六氫吡𠯤－１－基］戊－２－烯腈治療患有認知障礙的個體之免疫性血小板減少症之方法 |